Related Experiment Video
Updated: May 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Multi-scale computational models of familial hypertrophic cardiomyopathy: genotype to phenotype
Stuart G Campbell1, Andrew D McCulloch
1Department of Bioengineering, University of California San Diego, , 9500 Gilman Drive, La Jolla, CA 92093-0412, USA.
Insights
Familial hypertrophic cardiomyopathy (FHC) is an inherited heart condition. Computational models integrating biophysical data can predict FHC progression and personalize patient treatment.
Area of Science:
- Cardiovascular Medicine
- Computational Biology
- Genetics
Background:
- Familial hypertrophic cardiomyopathy (FHC) is a genetic disorder affecting approximately 1 in 500 individuals.
- Characterized by ventricular wall thickening, FHC can lead to heart failure and sudden cardiac death.
- Disease presentation varies significantly, complicating treatment and risk assessment.
Purpose of the Study:
- To explore the potential of multi-scale computational models in understanding and managing FHC.
- To integrate detailed biophysical data with cardiac cell dynamics, tissue properties, and hemodynamics.
- To predict heart function and identify genotype-based therapeutic strategies.
Main Methods:
- Utilizing detailed biophysical data of sarcomeric proteins.
- Developing computational models that simulate cardiac cell function, myocardial tissue properties, and heart geometry.
- Integrating hemodynamic load into multi-scale simulations.
Main Results:
- Recent advances allow accurate representation of FHC-linked mutant proteins in simulations.
- Models can predict early-stage contractile dysfunction and altered myocardial strain patterns.
- These predictions offer potential for validation in genetically modified animal models.
Conclusions:
- Multi-scale computational models show promise for early FHC detection and understanding.
- These models can lead to genotype-based risk stratification for FHC patients.
- Long-term potential includes personalized therapy development for improved clinical management of FHC.
Abstract:
Familial hypertrophic cardiomyopathy (FHC) is an inherited disorder affecting roughly one in 500 people. Its hallmark is abnormal thickening of the ventricular wall, leading to serious complications that include heart failure and sudden cardiac death. Treatment is complicated by variation in the severity, symptoms and risks for sudden death within the patient population. Nearly all of the genetic lesions associated with FHC occur in genes encoding sarcomeric proteins, indicating that defects in cardiac muscle contraction underlie the condition. Detailed biophysical data are increasingly available for computational analyses that could be used to predict heart phenotypes based on genotype. These models must integrate the dynamic processes occurring in cardiac cells with properties of myocardial tissue, heart geometry and haemodynamic load in order to predict strain and stress in the ventricular walls and overall pump function. Recent advances have increased the biophysical detail in these models at the myofilament level, which will allow properties of FHC-linked mutant proteins to be accurately represented in simulations of whole heart function. The short-term impact of these models will be detailed descriptions of contractile dysfunction and altered myocardial strain patterns at the earliest stages of the disease-predictions that could be validated in genetically modified animals. Long term, these multi-scale models have the potential to improve clinical management of FHC through genotype-based risk stratification and personalized therapy.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Pharmacogenomics: Identification of New Drug Targets

